Search - tctmd.com

Displaying 441 - 460 of 855

Sort: Relevancy | Date

News Opinion CV Team Dispatch

March 2022 News Roundup

L.A. McKeown

March 01, 2022

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

News Daily News

Robert M. Califf Becomes 25th Commissioner of the US FDA

L.A. McKeown

February 15, 2022

News Conference News THT 2022

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

L.A. McKeown

February 07, 2022

News Conference News STS 2022

Tricuspid Repair During Mitral Valve Surgery Prevents TR Progression

Michael O'Riordan

February 04, 2022

News Conference News STS 2022

Modified Surgical MV Repair Stands Up to Replacement

Michael O'Riordan

February 03, 2022

News Conference News THT 2022

PA Pressure Monitoring Useful Even in Presymptomatic CHF Patients

L.A. McKeown

February 03, 2022

Presentation THT 2022

Executing Clinical Follow Up In the Modern Era

Presenter: Jodi Akin

February 02, 2022

Presentation THT 2022

Clinical Trials During COVID-19: Innvestigator Perspective

Presenter: Scott Solomon

February 02, 2022

Presentation THT 2022

Research Consortium / Collabratories

Presenter: Mona Fiuzat

February 02, 2022

Presentation THT 2022

Challenges With Cardiogenic Shock Studies in the US

Presenter: Chuck Simonton

February 02, 2022

Presentation THT 2022

Innovation in Heart Failure Trial Designs

Presenter: Ori Ben-Yehuda

February 02, 2022

Presentation THT 2022

Heart Failure Trials in the Modern Era: Where Are We Going?

Presenter: Andrew Farb

February 02, 2022

Presentation THT 2022

Efficacy of Hemodynamic-Guided Heart Failure Management in Patients Enrolled With Elevated Natriuretic Peptide Levels but Without a Recent HF Hospitalization: An Analysis of the GUIDE-HF Trial

Presenter: Akshay Desai

February 02, 2022

News Industry News

Landmark REDUCE LAP-HF II Trial Demonstrates Clinical Benefit of Corvia Atrial Shunt in Large Segment of Heart Failure Patients

February 02, 2022

News Conference News THT 2022

REDUCE LAP-HF II: Atrial Shunt Device Comes Up Short in HFpEF

Shelley Wood

February 01, 2022

Presentation THT 2022

Results From First-In-Human Clinical Trial of RP-A501 (AAV9:LAMP2B) Gene Therapy Treatment for Danon Disease

Presenter: Barry Greenberg

February 01, 2022

Presentation THT 2022

Current status of the REBALANCE-HF US FDA randomized feasibility clinical trial in HFpEF

Presenter: Sanjiv Shah

February 01, 2022

Presentation THT 2022

Featured Lecture: How to Incorporate New Therapies and In What Order -- Ahead of the Guidelines

Presenter: Milton Packer

February 01, 2022

Presentation THT 2022

Omecamtiv Mecarbil - Is It More Effective in Low EFs

Presenter: John Teerlink

February 01, 2022

Advertisement

March 2022 News Roundup

FDA Approves Empagliflozin for Treatment of HFpEF

Robert M. Califf Becomes 25th Commissioner of the US FDA

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

Tricuspid Repair During Mitral Valve Surgery Prevents TR Progression

Modified Surgical MV Repair Stands Up to Replacement

PA Pressure Monitoring Useful Even in Presymptomatic CHF Patients

Executing Clinical Follow Up In the Modern Era

Clinical Trials During COVID-19: Innvestigator Perspective

Research Consortium / Collabratories

Challenges With Cardiogenic Shock Studies in the US

Innovation in Heart Failure Trial Designs

Heart Failure Trials in the Modern Era: Where Are We Going?

Efficacy of Hemodynamic-Guided Heart Failure Management in Patients Enrolled With Elevated Natriuretic Peptide Levels but Without a Recent HF Hospitalization: An Analysis of the GUIDE-HF Trial

Landmark REDUCE LAP-HF II Trial Demonstrates Clinical Benefit of Corvia Atrial Shunt in Large Segment of Heart Failure Patients

REDUCE LAP-HF II: Atrial Shunt Device Comes Up Short in HFpEF

Results From First-In-Human Clinical Trial of RP-A501 (AAV9:LAMP2B) Gene Therapy Treatment for Danon Disease

Current status of the REBALANCE-HF US FDA randomized feasibility clinical trial in HFpEF

Featured Lecture: How to Incorporate New Therapies and In What Order -- Ahead of the Guidelines

Omecamtiv Mecarbil - Is It More Effective in Low EFs

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content